Back to News
Market Impact: 0.2
Immunic Plans Phase 3 Progressive MS Trial After Mixed Phase 2 Results
Source: marketbeat.com
Healthcare & BiotechCompany Fundamentals
Immunic is preparing a Phase 3 trial of experimental multiple sclerosis drug vidofludimus calcium for progressive disease. The company expects first-patient enrollment in the first half of 2027; the article provides no trial results or financial figures.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
IMUX0.20
More News
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- Fox completes its $22B acquisition of Roku
- Elanco Shares Jump After Q3 Beat and Outlook Raise
- Paraguay’s Santiago Pena under arrest, new president Pedro Alliana sworn in
- FIGS Beats Earnings as Demand Outstrips Supply, CEO Trina Spear Says
- OpenAI valued at $1.25 trillion, as rival Anthropic nears its IPO